TinyGemsBreaks – Oragenics Inc. (NYSE American: OGEN) Files 2025 Form 10-K And Provides Operational Update
Oragenics (NYSE American: OGEN) announced the filing of its Annual Report on Form 10-K for the year ended Dec. 31, 2025, alongside a shareholder update highlighting operational, clinical and financial progress. The company reported key 2025 milestones including restored NYSE American compliance, a $16.5 million capital raise, U.S.-based drug manufacturing transition and advancement of its ONP-002 program, while outlining early 2026 progress toward Phase IIa trial initiation in Australia and strategic priorities focused on patient enrollment, U.S. regulatory advancement and expansion of its CNS pipeline. To view the full press release, visit https://ibn.fm/Dg7JA About Oragenics, Inc. Oragenics, Inc. is a…

